Lonza received Swissmedic approval and a GMP license for a new aseptic drug‑product filling line in Stein (Switzerland), adding high‑containment capabilities for highly potent biologics including ADCs and enabling integrated drug‑substance to drug‑product workflows. Lonza positioned the expansion as a strategic strengthening of its end‑to‑end biologics offering for clinical and commercial customers. Separately, MilliporeSigma (Merck KGaA’s Life Science business) agreed to acquire JSR Life Sciences’ chromatography business to expand downstream processing options, notably Protein A resins used in monoclonal antibody purification. Both moves underscore continued investment in biologics manufacturing capacity and upstream/downstream integration as sponsors aim to derisk late‑stage programs and accelerate time to market. Clarification: Protein A chromatography is the industry standard capture step for purifying IgG‑class monoclonal antibodies and is central to scalable antibody manufacturing.